| Previous close | 33.38 |
| Open | 33.33 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 33.26 - 33.49 |
| 52-week range | 29.83 - 35.38 |
| Volume | 10,558,641 |
| Avg. volume | 19,421,421 |
| Market cap | 199.09B |
| Beta | 1.05 |
| PE ratio (TTM) | 28.08 |
| EPS (TTM) | 1.19 |
| Earnings date | 30 Oct 2017 - 3 Nov 2017 |
| Dividend & yield | 1.28 (3.83%) |
| Ex-dividend date | 2017-08-02 |
| 1y target est | 37.45 |
- InvestorPlace•12 hours ago
The Bull Case for Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Weak
Giving credit where credit is due, I do think Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stock looks stronger than it did just a couple of quarters ago. VRX stock has still declined 1.5% so far this year, but the narrative surrounding the company has certainly changed. On the Q2 conference call, Valeant management made a big deal of the fact that 73% of Q2 revenue came from Bausch & Lomb and the Salix business.
- CNBC•yesterday
Trump doesn't 'know the facts' when he says Merck is shipping jobs overseas
The president may want to check his facts on Merck, which he accused of "taking jobs out of the U.S."
- Market Realist•yesterday
Pfizer’s Corporate and Pipeline Developments in 2Q17
Apart from Pfizer’s (PFE) product developments, let's take a look at some recent pipeline and corporate developments.
